BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20652725)

  • 1. EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.
    Burel-Vandenbos F; Benchetrit M; Miquel C; Fontaine D; Auvergne R; Lebrun-Frenay C; Cardot-Leccia N; Michiels JF; Paquis-Flucklinger V; Virolle T
    J Neurooncol; 2011 Apr; 102(2):171-8. PubMed ID: 20652725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.
    Burel-Vandenbos F; Turchi L; Benchetrit M; Fontas E; Pedeutour Z; Rigau V; Almairac F; Ambrosetti D; Michiels JF; Virolle T
    Neuro Oncol; 2013 Oct; 15(10):1278-88. PubMed ID: 23935154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
    Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
    Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
    Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
    J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low grade diffuse gliomas: shared cellular composition and morphometric differences.
    Kinjo S; Hirato J; Nakazato Y
    Neuropathology; 2008 Oct; 28(5):455-65. PubMed ID: 18282166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.
    Debinski W; Slagle B; Gibo DM; Powers SK; Gillespie GY
    J Neurooncol; 2000 Jun; 48(2):103-11. PubMed ID: 11083073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
    Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
    Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
    PIAO YS; LU DH; ZHANG XJ; TANG GC; YANG H
    Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):156-60. PubMed ID: 21575384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
    Rao S; Rajkumar A; Sundaram S; Joyce ME; Duvuru P
    J Cancer Res Ther; 2020; 16(6):1476-1481. PubMed ID: 33342816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy.
    Marquez A; Wu R; Zhao J; Tao J; Shi Z
    Diagn Mol Pathol; 2004 Mar; 13(1):1-8. PubMed ID: 15163002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping.
    Higgins RJ; Dickinson PJ; LeCouteur RA; Bollen AW; Wang H; Wang H; Corely LJ; Moore LM; Zang W; Fuller GN
    J Neurooncol; 2010 May; 98(1):49-55. PubMed ID: 19967449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.
    Reifenberger J; Ring GU; Gies U; Cobbers L; Oberstrass J; An HX; Niederacher D; Wechsler W; Reifenberger G
    J Neuropathol Exp Neurol; 1996 Jul; 55(7):822-31. PubMed ID: 8965097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells.
    Kupp R; Shtayer L; Tien AC; Szeto E; Sanai N; Rowitch DH; Mehta S
    Cell Rep; 2016 Sep; 16(11):2838-2845. PubMed ID: 27626655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
    Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
    J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric- and adult-type gliomas.
    Aboubakr O; Métais A; Maillard J; Hasty L; Brigot E; Berthaud C; Lacombe J; Pucelle N; Raynal J; Appay R; Varlet P; Tauziède-Espariat A
    Histopathology; 2024 Apr; 84(5):893-899. PubMed ID: 38253970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
    Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
    Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 protein and epidermal growth factor receptor expression in human astrocytomas.
    Kordek R; Biernat W; Alwasiak J; Maculewicz R; Yanagihara R; Liberski PP
    J Neurooncol; 1995 Oct; 26(1):11-6. PubMed ID: 8583240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
    Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
    Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
    Sipayya V; Sharma I; Sharma KC; Singh A
    J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.